Hepatocellular Carcinoma, Very-early Stage
Conditions
Keywords
treatments, hepatocellular carcinoma
Brief summary
The aim of our study was to elucidate the difference in the rates of complication, hospitalization days, medical expenses, MRI showed that the degree of tumor necrosis, and overall survival rates of the therapies between PEI, MVA and RFA, and make the standard for minimally invasive treatment of very early stage HCC.
Interventions
PROCEDURERFA
PROCEDUREMWV
PROCEDUREPEI
Percutaneous ethanol injection
Sponsors
Eastern Hepatobiliary Surgery Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Preoperative clinical, imaging and tumor markers were diagnosed as hepatocellular carcinoma 2. Tumor diameter\<2cm 3. Child-Pugh class A liver function 4. Without major organ dysfunction 5. male or female patients \> 18 years and \<=70 years of age 6. Voluntary participation in this clinical trial
Exclusion criteria
1. Other anticancer treatment before therapy 2. Patients with apparent major organs (i.e. cardiac, pulmonary, cerebral and renal) dysfunction, which may affect the treatment of liver cancer 3. Patients with other diseases that may affect the treatment of this treatment 4. History of other malignant tumors 5. Patients who are participating in other clinical trials 6. Pregnant, lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence | 3 years | Hepatocellular Carcinoma will recurrence in 3 years |
| Death | 3 years | — |
Countries
China
Outcome results
None listed